Evidence map›Paper›PMID 37631852›Full record

ArticleVaccines2023

SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients.

Natacha Bordry, Anne-Claire Mamez, Chiara Fedeli, Chloé Cantero, Cyril Jaksic, Pilar Ustero Alonso, Caroline Rayroux, Gregory Berra, Vera Portillo, Maeva Puntel and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Natacha BordryDepartment of Oncology, Geneva University Hospitals, University of Geneva and Swiss Cancer Center Leman, 1205 Geneva, Switzerland.ORCID 0000-0002-3523-438X
Anne-Claire MamezDepartment of Haematology, Geneva University Hospitals and Faculty of Medicine University of Geneva, 1205 Geneva, Switzerland.
Chiara FedeliDepartment of Infectious Diseases, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Chloé CanteroDepartment of Pneumology, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0001-9047-0505
Cyril JaksicCRC & Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, 1205 Geneva, Switzerland.ORCID 0000-0001-5835-3480
Pilar Ustero AlonsoDepartment of Infectious Diseases, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Caroline RayrouxDepartment of Pneumology, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Gregory BerraDepartment of Pneumology, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Vera PortilloDepartment of Infectious Diseases, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Maeva PuntelDepartment of Infectious Diseases, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Sabine YerlyLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals & Faculty of Medicine, 1205 Geneva, Switzerland.
Sébastien BugeiaDepartment of Oncology, Geneva University Hospitals, University of Geneva and Swiss Cancer Center Leman, 1205 Geneva, Switzerland.
Garance GutknechtDepartment of Oncology, Geneva University Hospitals, University of Geneva and Swiss Cancer Center Leman, 1205 Geneva, Switzerland.
Mariagrazia Di MarcoDepartment of Oncology, Geneva University Hospitals, University of Geneva and Swiss Cancer Center Leman, 1205 Geneva, Switzerland.
Nicolas MachDepartment of Oncology, Geneva University Hospitals, University of Geneva and Swiss Cancer Center Leman, 1205 Geneva, Switzerland.ORCID 0000-0001-8944-1088
Paola Marina SoccalDepartment of Pneumology, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Yves ChalandonDepartment of Haematology, Geneva University Hospitals and Faculty of Medicine University of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0001-9341-8104
Alexandra CalmyDepartment of Infectious Diseases, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.
Alfredo AddeoDepartment of Oncology, Geneva University Hospitals, University of Geneva and Swiss Cancer Center Leman, 1205 Geneva, Switzerland.ORCID 0000-0003-0988-0828
University of Geneva · CHUniversity Hospital of Geneva · CH

Funding

University Hospitals Geneva Medical Center Research & Development Program
6 · The paper itself

Abstract

Immunocompromised patients (ICPs) have a higher risk of developing severe forms of COVID-19 and experience a higher burden of complications and mortality than the general population. However, recent studies have suggested that the antibody response to SARS-CoV-2 mRNA vaccines could be highly variable among different ICPs. Using a collaborative, monocentric, prospective cohort study, we assessed anti-SARS-CoV-2 spike protein antibody titers following two and three doses of mRNA vaccines in four groups of ICPs (cancer [

Indexed as

immunodeficiencymRNA vaccinesSARS-CoV-2

Identifiers

PMID37631852
PMCPMC10459936
OpenAlexW4385358072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.